Skip to content

The Serum Sclerostin Levels in Cholesteatoma Patients

The Serum Sclerostin Levels in Cholesteatoma Patients

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03954288
Enrollment
75
Registered
2019-05-17
Start date
2019-03-29
Completion date
2020-03-15
Last updated
2019-05-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cholesteatoma, Otitis Media Chronic

Keywords

otitis media chronic, cholesteatoma, sclerostin

Brief summary

The aim of this study is to investigate the levels of sclerostin in patients with cholesteatoma. So far, there is no study showing the levels of sclerostin in cholesteatoma. The investigators hope that the results of our study will start new processes that can be used in the clinic.

Detailed description

Chronic otitis media (COM) is the perforation of the eardrum and mucosal inflammation of the space in the middle ear and the air cavities of the temporal bone over a period of three months. Although COM is defined as a multifactorial disease, its etiopathogenesis has not been fully elucidated. Cholesteatoma is a condition that disrupts the balance between bone formation and resorption in COM. The cholesteatoma is a destructive squamous epithelial lesion of temporal bone, it gradually expands and leads to serious complications by the destruction of near bone structures, ossicular chain and otic capsule. A growing debate examines the role of bone formation and destruction with osteoblasts, osteocytes and osteoclast cells in cholesteatoma formation. Sclerostin is a glycoprotein that plays a role in the regulation of bone metabolism secreted by osteocytes. Antibodies directed against sclerostin stimulate bone formation and represent a new therapeutic option for the treatment of increased bone resorption diseases, such as osteoporosis and generalized bone loss, inflammatory diseases with cartilage damage. The aim of this study is to investigate the levels of sclerostin in patients with cholesteatoma. So far, there is no study showing the levels of sclerostin in cholesteatoma. The investigators hope that the results of our study will start new processes that can be used in the clinic.

Interventions

DIAGNOSTIC_TESTserum for sclerostin ELISA test

Blood sample to measure serum sclerostin level

Sponsors

Abant Izzet Baysal University
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
No

Inclusion criteria

cholesteatoma chronic otitis media

Exclusion criteria

Acute infection Malignancy

Design outcomes

Primary

MeasureTime frameDescription
change of the levels of sclerostin in cholesteatoma at 1 month1 monthSo far, there is no study showing the levels of sclerostin in cholesteatoma. The investigators hope that the results of our study will initiate new processes that can be used in clinical applications.

Countries

Turkey (Türkiye)

Contacts

Primary Contactözgür m yis
dromyis@mynet.com05324940572

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026